BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 31861748)

  • 1. Allometric Scaling Approaches for Predicting Human Pharmacokinetic of a Locked Nucleic Acid Oligonucleotide Targeting Cancer-Associated miR-221.
    Di Martino MT; Arbitrio M; Fonsi M; Erratico CA; Scionti F; Caracciolo D; Tagliaferri P; Tassone P
    Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31861748
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study.
    Tassone P; Di Martino MT; Arbitrio M; Fiorillo L; Staropoli N; Ciliberto D; Cordua A; Scionti F; Bertucci B; Salvino A; Lopreiato M; Thunarf F; Cuomo O; Zito MC; De Fina MR; Brescia A; Gualtieri S; Riillo C; Manti F; Caracciolo D; Barbieri V; Di Paola ED; Di Francesco AE; Tagliaferri P
    J Hematol Oncol; 2023 Jun; 16(1):68. PubMed ID: 37365583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats.
    Di Martino MT; Arbitrio M; Caracciolo D; Scionti F; Tagliaferri P; Tassone P
    Mol Ther Nucleic Acids; 2020 Jun; 20():73-85. PubMed ID: 32146420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells.
    Di Martino MT; Gullà A; Gallo Cantafio ME; Altomare E; Amodio N; Leone E; Morelli E; Lio SG; Caracciolo D; Rossi M; Frandsen NM; Tagliaferri P; Tassone P
    PLoS One; 2014; 9(2):e89659. PubMed ID: 24586944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and Pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in Mice and Non-human Primates.
    Gallo Cantafio ME; Nielsen BS; Mignogna C; Arbitrio M; Botta C; Frandsen NM; Rolfo C; Tagliaferri P; Tassone P; Di Martino MT
    Mol Ther Nucleic Acids; 2016 Jun; 5(6):. PubMed ID: 27327137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-361-3p is a potent therapeutic target for oral squamous cell carcinoma.
    Ogawa H; Nakashiro KI; Tokuzen N; Kuribayashi N; Goda H; Uchida D
    Cancer Sci; 2020 May; 111(5):1645-1651. PubMed ID: 32086979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Locked nucleic acid anti-miR-21 inhibits cell growth and invasive behaviors of a colorectal adenocarcinoma cell line: LNA-anti-miR as a novel approach.
    Nedaeinia R; Sharifi M; Avan A; Kazemi M; Rafiee L; Ghayour-Mobarhan M; Salehi R
    Cancer Gene Ther; 2016 Aug; 23(8):246-53. PubMed ID: 27364574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LNA-anti-miR-150 ameliorated kidney injury of lupus nephritis by inhibiting renal fibrosis and macrophage infiltration.
    Luan J; Fu J; Chen C; Jiao C; Kong W; Zhang Y; Chang Q; Wang Y; Li D; Illei GG; Kopp JB; Pi J; Zhou H
    Arthritis Res Ther; 2019 Dec; 21(1):276. PubMed ID: 31829247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The first analogues of LNA (locked nucleic acids): phosphorothioate-LNA and 2'-thio-LNA.
    Kumar R; Singh SK; Koshkin AA; Rajwanshi VK; Meldgaard M; Wengel J
    Bioorg Med Chem Lett; 1998 Aug; 8(16):2219-22. PubMed ID: 9873516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LNA-mediated microRNA silencing in non-human primates.
    Elmén J; Lindow M; Schütz S; Lawrence M; Petri A; Obad S; Lindholm M; Hedtjärn M; Hansen HF; Berger U; Gullans S; Kearney P; Sarnow P; Straarup EM; Kauppinen S
    Nature; 2008 Apr; 452(7189):896-9. PubMed ID: 18368051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic inhibition of microRNA-21 (miR-21) using locked-nucleic acid (LNA)-anti-miR and its effects on the biological behaviors of melanoma cancer cells in preclinical studies.
    Javanmard SH; Vaseghi G; Ghasemi A; Rafiee L; Ferns GA; Esfahani HN; Nedaeinia R
    Cancer Cell Int; 2020; 20():384. PubMed ID: 32788885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo activity of miR-92a-Locked Nucleic Acid (LNA)-Inhibitor against endometrial cancer.
    Torres A; Kozak J; Korolczuk A; Wdowiak P; Domańska-Glonek E; Maciejewski R; Torres K
    BMC Cancer; 2016 Oct; 16(1):822. PubMed ID: 27782822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-20a inhibition using locked nucleic acid (LNA) technology and its effects on apoptosis of human macrophages infected by Toxoplasma gondii RH strain.
    Rezaei F; Daryani A; Sharifi M; Sarvi S; Jafari N; Pagheh AS; Hashemi N; Hejazi SH
    Microb Pathog; 2018 Aug; 121():269-276. PubMed ID: 29800695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial observations of 99mTc labelled locked nucleic acids for antisense targeting.
    Zhang Y; He J; Liu G; Venderheyden JL; Gupta S; Rusckowski M; Hnatowich DJ
    Nucl Med Commun; 2004 Nov; 25(11):1113-8. PubMed ID: 15577590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Nonclinical Pharmacokinetics and Prediction of Human Pharmacokinetics of SPH3127, a Novel Direct Renin Inhibitor.
    Zhang L; Mao Y; Gao Z; Chen X; Li X; Liu Y; Xia G
    Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):15-26. PubMed ID: 31494843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-221 stimulates breast cancer cells and cancer-associated fibroblasts (CAFs) through selective interference with the A20/c-Rel/CTGF signaling.
    Santolla MF; Lappano R; Cirillo F; Rigiracciolo DC; Sebastiani A; Abonante S; Tassone P; Tagliaferri P; Di Martino MT; Maggiolini M; Vivacqua A
    J Exp Clin Cancer Res; 2018 May; 37(1):94. PubMed ID: 29716623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and validation of a bioanalytical method for quantification of LNA-i-miR-221, a 13-mer oligonucleotide, in rat plasma using LC-MS/MS.
    Franzoni S; Vezzelli A; Turtoro A; Solazzo L; Greco A; Tassone P; Di Martino MT; Breda M
    J Pharm Biomed Anal; 2018 Feb; 150():300-307. PubMed ID: 29268195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver.
    Elmén J; Lindow M; Silahtaroglu A; Bak M; Christensen M; Lind-Thomsen A; Hedtjärn M; Hansen JB; Hansen HF; Straarup EM; McCullagh K; Kearney P; Kauppinen S
    Nucleic Acids Res; 2008 Mar; 36(4):1153-62. PubMed ID: 18158304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Locked nucleic acid-inhibitor of miR-205 decreases endometrial cancer cells proliferation in vitro and in vivo.
    Torres A; Kozak J; Korolczuk A; Rycak D; Wdowiak P; Maciejewski R; Torres K
    Oncotarget; 2016 Nov; 7(45):73651-73663. PubMed ID: 27655663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. microRNA-181a-5p antisense oligonucleotides attenuate osteoarthritis in facet and knee joints.
    Nakamura A; Rampersaud YR; Nakamura S; Sharma A; Zeng F; Rossomacha E; Ali SA; Krawetz R; Haroon N; Perruccio AV; Mahomed NN; Gandhi R; Rockel JS; Kapoor M
    Ann Rheum Dis; 2019 Jan; 78(1):111-121. PubMed ID: 30287418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.